Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Explore the key differences between permissioned and permissionless systems in one concise intro. This overview highlights tradeoffs in security, scalability, and governance to help you decide which model suits your project.
21,465 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Strategy’s stock soared february, jumping 35% from its February low and outpacing bitcoin’s gains as investors price ...
When a chief operating officer sells stock, investors take notice. This article breaks down the implications, explain...
Zoom's post-pandemic growth trajectory remains uncertain as investors weigh AI opportunities and competition. This pi...
Match Group’s HR chief outlines a policy-first approach to workplace romances, arguing transparency and clear disclos...
Ripple's latest private-market move values the company at $50 billion and signals confidence in its ecosystem, even a...
Mining stocks are delivering outsized gains in a fresh gold rally, outpacing bullion as risk assets rebound and infla...
A growing wave of funds aims to turn congressional stock disclosures into tradable signals, but investors face questi...
IBM is quietly reshaping its story with a serious quantum strategy, strong enterprise demand, and a durable dividend....
Capgemini’s strategy chief says the idea that AI will eliminate consultants is overstated, arguing transformation wor...
A big EBITDA leap can capture attention, but insider trades often tell a different story. This guide explains why thi...
Markets showed modest gains as the Fed meeting kicked off, with tech and travel shares helping lift indexes. This gui...